Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | UK NCRI AML17 trial update: everolimus addition for consolidation

Robert Hills • 5 Oct 2018
ESH MM 2018
Acute Myeloid Leukemia Leukemia Everolimus
AML17

Robert Hills of the University of Oxford, Oxford, UK, gives us an update on the addition of the mTOR inhibitor everolimus to consolidation therapy in the UK NCRI AML17 trial (ISRCTN55675535). Prof. Hills describes the results so far, which while not favourable for this specific combination do not rule it out as an effective option in other settings. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Robert Hills

Judging the value of a clinical trial in hem-onc
2:24
Judging the value of a clinical trial in hem-onc
Robert Hills • 5 Oct 2018
Opinion: value of MRD as an endpoint in hem-onc clinical trials
2:17
Opinion: value of MRD as an endpoint in hem-onc clinical trials
Robert Hills • 5 Oct 2018

Related Videos

Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
2:04
Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
Farhad Ravandi • 21 Sep 2026
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
1:40
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
Farhad Ravandi • 21 Sep 2026
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals